A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.
IPS cells have created excitement among researchers who see them as more available, easier to make, and less ethically conflicted than embryonic stem cells...
The anti-amyloid antibody becomes the first Alzheimer’s treatment in 20 years to receive traditional approval from the FDA. Broader Medicare coverage starts now.
Every week in a Finnish operating room, bits of human cortex get lifted from brains and straight into electrophysiology rigs. Other tissues go to diagnostic and research labs, or biobanks, for ADRD research. Read how it happens.
Scientists have established acute slice recordings from cerebral cortex biopsies. They find circuitry and basic function to be preserved. They also find changes in the presence of Alzheimer's pathology.
In the Graduate trials, the anti-amyloid antibody gantenerumab cleared only half as much plaque as it had done in earlier studies. Is formulation or dosing to blame?
While each disease features distinct proteomes in the brain, cerebrospinal fluid, and blood, some proteins overlap. They are more dysregulated in familial than in sporadic AD.
Synuclein fibrils from Parkinson’s disease, PD dementia, and dementia with Lewy bodies share the same protofilament structure. MSA fibrils are different.
Clearance triggers improvement in downstream markers of inflammation and neurodegeneration—but not in those who started with high tangle burden. (Clue: women.)
Donanemab Data Anchors Upbeat AAIC Give BACE Inhibitors a Second Chance? CSF MTBR-tau-243 Tracks Tangles, Plummets in Response to Antibody Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD Spying on α-Synuclein Inclusions: PET Tracers In
The NIA invites scientists to submit data to create diverse, open datasets and design diagnostic algorithms for more accurate, early prediction of Alzheimer’s.